中国当代医药
中国当代医药杂志欢迎您 今天是   2025年4月8日星期二
设为首页  加入收藏  联系我们         
 
      首 页    |    本刊简介     |    期刊荣誉     |    编采团队     |    会务培训     |    理事单位     |    下载专区     |    在线留言     |    联系我们     |     返回中国当代医药网
中国当代医药  2023, Vol. 30 Issue (21): 80-83    
  妇幼医学 本期目录 | 过刊浏览 | 高级检索 |
左乙拉西坦联合奥卡西平治疗癫痫患儿的效果
刘 楠 谢惠源 李 尖 朱建萍
广东省中山市博爱医院儿科,广东中山 528400
Effect of Levetiracetam combined with Oxcarbazepine in the treatment of children with epilepsy
LIU Nan XIE Huiyuan LI Jian ZHU Jianping
Department of Pediatrics,Boai Hospital Of Zhongshan,Guangdong Province,Zhongshan 528400,China
全文: PDF (570 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的 探究左乙拉西坦联合奥卡西平治疗癫痫患儿的效果。方法 选取2020 年8 月至2022 年7 月中山市博爱医院儿科收治92 例癫痫患儿作为研究对象,按随机数字表法分为对照组(46 例)与研究组(46 例),比较两组脑电图治疗效果、免疫功能[免疫球蛋白(Ig):IgA、IgM、IgG、T 淋巴细胞亚群:CD3+、CD4+]、认知功能[总智商(FIQ)、操作智商(PIQ)、计算语言智商(VIQ)]和不良反应。结果 研究组治疗后脑电图治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗前,两组IgA、IgM、IgG、CD3+、CD4+水平比较,差异无统计学意义(P>0.05);治疗后,两组IgA、IgM、IgG 水平低于治疗前,CD3+、CD4+水平高于本组治疗前,且研究组IgA、IgM、IgG 水平低于对照组,CD3+、CD4+水平高于对照组,差异有统计学意义(P<0.05)。治疗前,两组FIQ、PIQ、VIQ 分数比较,差异无统计学意义(P>0.05);治疗后,两组FIQ、PIQ、VIQ 分数高于本组治疗前,且研究组FIQ、PIQ、VIQ 分数高于对照组,差异有统计学意义(P<0.05);治疗后两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论 左乙拉西坦联合奥卡西平能有效改善癫痫患儿的脑电图痫样放电,利于调节患儿免疫功能,减少对患儿认知功能的损伤,安全可靠。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
关键词 儿童癫痫左乙拉西坦奥卡西平免疫功能认知功能    
Abstract:Objective To explore the effect of Levetiracetam combined with Oxcarbazepine in the treatment of children with epilepsy.Methods From August 2020 to July 2022,92 children with epilepsy admitted to the Department of Pediatrics of Boai Hospital Of Zhongshan were selected as the study subjects.They were divided into the control group(46 cases)and the study group (46 cases) according to random number table method.The therapeutic effect of EEG and immune function(immunoglobulin [Ig]: IgA,IgM,IgG,T lymphocyte subgroup: CD3+,CD4+) cognitive function (full intelligence quotient[FIQ],performance intelligence quotient [PIQ],verpal intelligence quotient [VIQ]),and adverse reactions of the two groups were compared.Results The total effective rate of EEG treatment in the study group was higher than that in the control group,the difference was statistically significant (P <0.05).Before treatment,there were no statistically significant differences in the levels of IgA,IgM,IgG,CD3+and CD4+between the two groups (P>0.05).After treatment,the levels of IgA,IgM and IgG in the two groups were lower than those before treatment,and the levels of CD3+and CD4+were higher than those before treatment,the levels of IgA,IgM and IgG in the study group were lower than those in the control group,and the levels of CD3+and CD4+were higher than those in the control group,with statistically significant differences (P<0.05).Before treatment,the scores of total intelligence quotient (FIQ),operational intelligence quotient (PIQ),computational language intelligence quotient(VIQ)in the two groups were not significantly different(P>0.05).After treatment,the scores of FIQ,PIQ and VIQ in the two groups were higher than those before treatment,and the scores of FIQ,PIQ and VIQ in the study group were higher than those in the control group,with statistically significant differences (P<0.05).After treatment,there was no statistically significant difference in total incidence of adverse reactions between the two groups (P>0.05).Conclusion Levetiracetam combined with Oxcarbazepine can effectively improve the epileptiform discharge of electroencephalogram in children with epilepsy,help regulate the immune function of children,reduce the damage to cognitive function of children,and is safe and reliable.
Key wordsEpilepsy in children    Levetiracetam    Oxcarbazepine    Immunity    Cognitive function
    
通讯作者: 朱建萍(1968-),女,主任医师;研究方向:儿童神经研究。   
作者简介: 刘楠(1982-),女,副主任医师;研究方向:儿童神经研究。
引用本文:   
刘楠; 谢惠源; 李尖; 朱建萍. 左乙拉西坦联合奥卡西平治疗癫痫患儿的效果[J]. 中国当代医药, 2023, 30(21): 80-83.
LIU Nan XIE Huiyuan LI Jian ZHU Jianping. Effect of Levetiracetam combined with Oxcarbazepine in the treatment of children with epilepsy. 中国当代医药, 2023, 30(21): 80-83.
链接本文:  
https://www.dangdaiyiyao.com/CN/     或     https://www.dangdaiyiyao.com/CN/Y2023/V30/I21/80
中华人民共和国互联网药品信息服务资格证书(京)-非经营性-2016-0092
京ICP备11001767号-6  京公网安备 11010502046607号  互联网药品信息服务资格证  期刊出版许可证  广告经营许可证
信息产业部备案管理系统网址 http://beian.miit.gov.cn/state/outPortal/loginPortal.action
投稿热线:010-59626690 总机:010-59626692/18/19/20   传真:010-59626204   投稿信箱:ddyy@vip.163.com
地址:北京市朝阳区东四环中路78号楼(大成国际中心B1座)8B02室   邮编:100124
技术支持:北京玛格泰克科技发展有限公司
Copyright 2000-2014 版权所有 《中国当代医药》杂志社 未经授权请勿转载